# Flexion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flexion-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Woburn, US
- Website: www.flexiontherapeutics.com
- Total disclosed funding: $75M
- Latest round: Series B (Dec 3, 2012)
- Investors on record: 6

## About

Flexion Therapeutics focuses on innovative solutions for managing pain and inflammation, primarily through advanced therapeutics that transform treatment paradigms in musculoskeletal disorders.Flexion Therapeutics specializes in the development of therapeutics for managing pain and inflammation, with its headquarters located in Woburn, US. Founded in 2007, the company has engaged in 5 different deals, with their most recent deal being an IPO on February 11, 2014, raising USD 65 mn through the sale of 5 million shares. The CEO of the company is Mike Clayman.Flexion Therapeutics develops pain management therapies aimed at transforming treatment for musculoskeletal disorders. Their primary product offering targets conditions requiring effective pain management solutions, designed for healthcare providers and patients alike. The company caters to diverse healthcare markets, ensuring their products meet the evolving needs of patients dealing with chronic pain and inflammation.In the financial year 2020, Flexion Therapeutics generated revenue of USD 85.55 mn, while reporting an EBITDA of USD -80.10 mn, indicating substantial investments in growth and product development.Following the successful IPO in February 2014, Flexion Therapeutics plans to leverage the raised funds to accelerate the development and launch of new therapeutic products aimed at chronic pain management. The company is also targeting expansion into additional geographic markets, focusing on regions with high unmet medical needs for pain management solutions. The funding will support these initiatives, fostering innovation and improving access to their products in these targeted markets.

## Funding rounds

- Series B, Dec 3, 2012, $20M — Sofinnova Partners, Versant Ventures, 5AM Ventures, Novo Holdings, Pfizer Venture Investments
- Series A, Jan 1, 2012, $13M — Sofinnova Partners, Versant Ventures, 5AM Ventures, Pfizer Venture Investments
- Series A, Jan 29, 2010, $9M — Pfizer Venture Investments
- Series A, Jun 8, 2009, $33M — Sofinnova Partners, Versant Ventures, 5AM Ventures, ROCH Capital

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- ROCH Capital (https://capitalatlas.ai/funds/roch-capital) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A, Series B
- Novo Holdings — Series B